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Background
Acute generalized exanthematous pustulosis (AGEP) is
rare cutaneous drug reaction involving drug-specific T
lymphocytes and neutrophilic inflammation. Imatinib is a
tyrosine kinase inhibitor used widely in treatment of
chronic myeloid leukemia (CML). Rash is a common side
effect of imatinib, occurring in up to 30% of patients.
However, there are only two case reports to date describ-
ing AGEP secondary to imatinib.
Case presentation
A 71-year-old woman known for chronic myeloid leuke-
mia presented with acute onset of generalized pruritus,
accompanied by small erythematous papules, and diffuse
general edema affecting the face, and upper and lower
extremities. The rash developed over a few hours and was
associated with shortness of breath, chills, and dysuria.
The rash persisted for 14 days at which point a 5 day
course of prednisone was prescribed which led to
improvement. Imatinib (generic) had been started
3 months earlier; was temporarily interrupted for 2-3
weeks after 1 month; then restarted 2 months prior to
onset of the rash. On exam there was pitting edema to
lower 2/3 anterior tibia, erythematous papular generalized
excoriated rash with xerosis. No blistering, sloughing of
skin, target lesions, or pustules. CBC normal, creatinine
unremarkable and urine negative for eosinophils.
Imatinib (generic) was discontinued and brand name
Gleevec ® was started. Two weeks later the rash recurred.
Eosinophil count increased to 2.84 x 109/L. A skin biopsy
was arranged which showed parakeratosis containing
neutrophils with formation of intracorneal pustules, in
keeping with AGEP.
Gleevec® was discontinued and Nilotinib 400mg PO
BID was substituted 2 weeks later. The rash resolved
and eosinophilia decreased over the next month and has
not recurred.
Conclusion
AGEP is a rare complication of imatinib therapy, and
should be considered in patients who present with atypi-
cal rash on imatinib.
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